biological activity | OSI-930 is an effective Kit (c-Kit), KDR and CSF-1R inhibitor with IC50 of 80 nM, 9 nM and 15 nM respectively. it has moderate inhibitory activity on Flt-1, c-Raf and Lck, and weak inhibitory activity on PDGFRα/β, Flt-3 and Abl. Phase 1. |
target | TargetValue FLT1 (Cell-Free Assay) 8 nM KDR (Cell-Free Assay) 9 nM CSF-1R (Cell-Free Assay) 15 nM LCK (Cell-Free Assay) 22 nM C- Raf (Cell-Free Assay) 41 nM |
Target | Value |
FLT1
(Cell-free assay)
| 8 nM |
KDR
(Cell-free assay)
| 9 nM |
CSF-1R
(Cell-free assay)
| 15 nM |
LCK
(Cell-free assay)
| 22 nM |
C-Raf
(Cell-free assay)
| 41 nM |
in vitro study | in vitro, OSI-930 effectively inhibit the activity of recombinant receptor tyrosine kinase. when acting on Kit, KDR, Flt, CSF-1R, c-Raf and Lck, the IC50 is 80 nM, 9 nM, 8 nM, 15 nM, 41 nM and 22 nM respectively. OSI-930 acts on HMC-1 cell lines to inhibit cell proliferation with IC50 of 14 nM, while acting on COLO-205 cells that do not express constitutively activated mutant receptor tyrosine kinase will not significantly inhibit growth. Moreover, OSI-930 also induced apoptosis of HMC-1 cells with EC50 of 34 nM. The latest research shows that OSI-930 inactivates purified recombinant cytochrome P450 (P450) 3A4 with K I of 24 μM, which is time-and concentration-dependent. |
in vivo study | OSI-930 was treated with oral feeding at the maximum effective dose of 200 mg/kg for various preclinical transplanted tumor models. Including HMC-1, NCI-SNU-5, COLO-205 and U251 transplanted tumor models, it has effective anti-tumor activity. |